CEO of Innexo, David Jonathan Benouaich, says his company is preparing for an exciting and robust 2022. The company, which is heavily invested in the biotechnology industry, has plans to expand in 2022. Innexo invests in the research and development of novel drugs and cell therapy used to treat illnesses and other medical conditions.